Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biochemotherapy vs Chemotherapy in Metastatic Melanoma
NCT00003027Phase 3Completed
- Sponsor
- Eastern Cooperative Oncology Group
- Start
- Nov 1997
- Primary completion
- Jul 2007
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of aldesleukin and interferon alfa-2b in melanoma (2 arms), sponsored by Eastern Cooperative Oncology Group. Primary endpoint: Overall Survival. Started Nov 1997; status: completed.
02
Drugs
aldesleukininterferon alfa-2b
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT00003027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003027.